These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2043774)

  • 21. Myelodysplastic/myeloproliferative neoplasms.
    Cazzola M; Malcovati L; Invernizzi R
    Hematology Am Soc Hematol Educ Program; 2011; 2011():264-72. PubMed ID: 22160044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
    Mozziconacci MJ; Caillères S; Maurice C; Vey N; Sainty D; Blaise D; Lafage-Pochitaloff M
    Leukemia; 2003 Sep; 17(9):1901-2. PubMed ID: 12970792
    [No Abstract]   [Full Text] [Related]  

  • 23. CD117 Expression as an aid to identify immature myeloid cells and foci of ALIP in bone marrow trephines.
    Naresh KN; Lampert IA
    Am J Hematol; 2006 Jan; 81(1):79. PubMed ID: 16369968
    [No Abstract]   [Full Text] [Related]  

  • 24. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.
    Chee YL; Vickers MA; Stevenson D; Holyoake TL; Culligan DJ
    Leukemia; 2003 Mar; 17(3):634-5. PubMed ID: 12646955
    [No Abstract]   [Full Text] [Related]  

  • 25. Prognostic significance of monocytosis in patients with myeloproliferative disorders.
    Beran M; Shen Y; Onida F; Wen S; Kantarjian H; Estey E
    Leuk Lymphoma; 2006 Mar; 47(3):417-23. PubMed ID: 16396764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes.
    Dickstein JI; Vardiman JW
    Am J Clin Pathol; 1993 Apr; 99(4):513-25. PubMed ID: 8475918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders.
    Bain BJ
    Leuk Lymphoma; 1999 Aug; 34(5-6):443-9. PubMed ID: 10492067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.
    So CC; Ma ES; Wan TS; Yip SF; Chan LC
    Leuk Res; 2008 Jun; 32(6):1000-1. PubMed ID: 17980911
    [No Abstract]   [Full Text] [Related]  

  • 29. Possible correlation of b3-a2-type bcr-abl messenger RNA defined by semiquantitative RT-PCR to platelet and megakaryocyte counts in Philadelphia-positive chronic myelogenous leukemia.
    Inokuchi K; Futaki M; Dan K; Nomura T
    Intern Med; 1994 Apr; 33(4):189-92. PubMed ID: 7520786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breakpoint cluster region, immunoglobulin, and T-cell receptor gene rearrangement analysis in juvenile chronic myelogenous leukemia.
    Farhi DC; Luckey CN; Siddiqui AM
    Mod Pathol; 1995 May; 8(4):389-93. PubMed ID: 7567936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
    Thiele J; Kvasnicka HM; Varus E; Ollig E; Schmitt-Graeff A; Staib P; Griesshammer M
    Leuk Lymphoma; 2004 Aug; 45(8):1627-31. PubMed ID: 15370216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment and characterization of a novel megakaryoblastic cell line, MOLM-1, from a patient with chronic myelogenous leukemia.
    Matsuo Y; Adachi T; Tsubota T; Imanishi J; Minowada J
    Hum Cell; 1991 Sep; 4(3):261-4. PubMed ID: 1782185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low megakaryocyte ploidy in Ph-positive chronic myelogenous leukemia measured by flow cytometry.
    Jacobsson S; Wadenvik H; Kutti J; Swolin B
    Am J Clin Pathol; 1999 Feb; 111(2):185-90. PubMed ID: 9930139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myeloid leukaemia in megakaryocytic crisis.
    Ranjitkumar S; Lindeman R
    Br J Haematol; 2002 Jun; 117(3):487. PubMed ID: 12028013
    [No Abstract]   [Full Text] [Related]  

  • 35. The distinctive micromegakaryocytes of transformed chronic myeloid leukemia.
    Fordham NJ; Stern S; Swansbury J; Bain BJ
    Am J Hematol; 2016 Mar; 91(3):350. PubMed ID: 26749024
    [No Abstract]   [Full Text] [Related]  

  • 36. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
    Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
    Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CML in megakaryocytic transformation and extramedullary infiltration.
    Kagotho E; Chang H
    Blood; 2020 Feb; 135(7):514. PubMed ID: 32197270
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical and cytogenetic correlations of abnormal megakaryocytopoiesis in patients with acute leukemia and chronic myelogenous leukemia in blast crisis.
    Lee EJ; Schiffer CA; Tomiyasu T; Testa JR
    Leukemia; 1990 May; 4(5):350-3. PubMed ID: 2388480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary fibrosis with megakaryocytoid cell infiltration and chronic myelogenous leukemia.
    Yamauchi K; Shimamura K
    Leuk Lymphoma; 1994 Oct; 15(3-4):253-9. PubMed ID: 7866273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Significance of histologic bone marrow evaluation in diagnosis of chronic granulocytic leukemia. II. Megakaryocytes].
    Komarnicki M; Rasińska M; Woźny T
    Acta Haematol Pol; 1995; 26(2):195-200. PubMed ID: 7653225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.